Neuronetics, Inc. filed its quarterly report on Form 10-Q with the SEC for the period ended September 30, 2026, disclosing improved revenue and a significantly reduced net loss compared to the prior-year quarter.

Key Highlights

  • Total revenues of $41,962 thousand for the three months ended September 30, 2026, up from $37,297 thousand in the same period of 2025, according to the filing.
  • Net loss of $1,556 thousand for Q3 2026, compared to a net loss of $9,401 thousand in Q3 2025, as reported in the filing.
  • Gross profit of $21,890 thousand for the third quarter of 2026, versus $17,108 thousand in the prior-year quarter.
  • Nine-month net loss of $15,800 thousand for the period ended September 30, 2026, compared to $31,929 thousand for the same period in 2025.
  • 77,728,311 shares of common stock outstanding as of October 28, 2026, the filing stated.
  • Total assets of $131,958 thousand as of September 30, 2026, down from $141,551 thousand at December 31, 2025.
  • Accumulated deficit of $474,843 thousand as of September 30, 2026, per the balance sheet.

Neuronetics Reports Q3 2026 Financial Results Across NeuroStar and Greenbrook Segments

Neuronetics, Inc. (NASDAQ:STIM), a smaller reporting company incorporated in Delaware and headquartered at 3222 Phoenixville Pike, Malvern, PA 19355, filed its Form 10-Q for the quarterly period ended September 30, 2026. The filing presents unaudited consolidated financial statements covering both the three- and nine-month periods ended September 30, 2026 and 2025. The company operates two revenue segments: NeuroStar and Greenbrook.

According to the filing, total revenues for the third quarter of 2026 were $41,962 thousand, consisting of $15,770 thousand from NeuroStar and $26,192 thousand from Greenbrook. This compares to total revenues of $37,297 thousand in Q3 2025, made up of $15,489 thousand from NeuroStar and $21,808 thousand from Greenbrook. For the nine months ended September 30, 2026, total revenues were $117,984 thousand, against $107,380 thousand for the same period in 2025. Total cost of revenues for Q3 2026 was $20,072 thousand, yielding gross profit of $21,890 thousand. The company reported income from operations of $541 thousand in Q3 2026, compared to a loss from operations of $7,321 thousand in Q3 2025. Interest expense for the quarter was $2,144 thousand.

On the balance sheet as of September 30, 2026, the filing reported cash and cash equivalents of $22,106 thousand, down from $28,134 thousand at December 31, 2025. Long-term debt, net, stood at $61,752 thousand, compared to $65,807 thousand at year-end 2025. Total stockholders' equity was $18,708 thousand and total equity, including a non-controlling interest of $3,695 thousand, was $22,403 thousand. Net loss per share attributable to Neuronetics stockholders for Q3 2026 was $(0.02), basic and diluted, on a weighted average share count of 77,004 thousand shares.

What Was Disclosed

Neuronetics filed its Q3 2026 Form 10-Q reporting total revenues of $41,962 thousand, a net loss of $1,556 thousand, and total assets of $131,958 thousand as of September 30, 2026, with 77,728,311 shares outstanding as of October 28, 2026.